Free cash flow remains deeply negative, with a $6.7 million outflow in 2026Q1 highlighting the company's total dependence on external financing to cover operational obligations.
| Cash from Operations | -8.02M | -1.79M | -7.64M | -16.07M | -1.04M | -1.44M |
| Operating CF Margin % | - | - | - | - | - | - |
| Operating CF Growth % | -1232.33% | 76.63% | 52.45% | -1439.33% | 27.61% | - |
| Net Income | -13.25M | -13.06M | -8.85M | -7.31M | -996.1K | -1.69M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 459.88K | 0 | 0 | 1.19M | 0 | 129.97K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 29.47K | 0 |
| Other Non-Cash Items | 293.53K | 657.16K | 509.33K | 0 | -654.07K | -1.43K |
| Working Capital Changes | 4.48M | 10.62M | 775.7K | -9.95M | 576.86K | 113.35K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 959 | 550.35K | -72.08K | -9.33M | 0 | 0 |
| Cash from Investing | 0 | 0 | 0 | 4.96M | 36.17M | -45.19M |
| Capital Expenditures | 0 | 0 | 3 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 4.96M | 0 | 0 |
| Cash from Financing | 9.52M | 2.25M | -489.43K | 12.79M | -35.56M | 5.53M |
| Debt Issued (Net) | 0 | 0 | -10M | 0 | 498.6K | 0 |
| Equity Issued (Net) | 10.4M | 2.37M | -68.61K | 8.67M | -36.11M | 5M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | -29.46K | -568.92K | -354.44K | -36.11M | -25K |
| Other Financing | -876.36K | -117.47K | 9.58M | 4.13M | 50K | 530.36K |
| Net Change in Cash | 1.51M | 467.39K | -8.13M | 1.69M | -438.07K | 4.09M |
| Free Cash Flow | -8.02M | -1.79M | -7.64M | -16.07M | -1.04M | -1.44M |
| FCF Margin % | - | - | - | - | - | - |
| FCF Growth % | -107.12% | 76.63% | 52.45% | -1439.33% | 27.61% | - |
| FCF per Share | -0.19 | -0.05 | -0.21 | -0.46 | -0.18 | -0.25 |
| FCF Conversion (FCF/Net Income) | 0.61x | 0.14x | 0.86x | 2.20x | 1.05x | 0.86x |
| Interest Paid | 0 | 0 | 0 | 2.66K | 0 | 0 |
| Taxes Paid | -13 | 0 | 1.6K | 1.6K | 0 | 0 |
Imminent liquidity and dilution risk
As reported in financial statements, the OCF/NI ratio has fluctuated wildly, reaching a high of 11.04 in 2023Q4, which indicates that net income is a poor proxy for the actual cash requirements of Estrella's preclinical development activities and ongoing operational obligations.
The extreme volatility in the relationship between net income and operating cash flow suggests that non-cash items and working capital swings are obscuring the true underlying cash burn. Investors should interpret these wide variances as a sign that GAAP earnings provide little utility for assessing the company's actual survival runway.
Based on Estrella's reported figures, free cash flow remains consistently negative, with a significant outflow of $6.7 million in 2026Q1 alone, highlighting the company's total reliance on external capital to fund its research-heavy business model without any offsetting commercial revenue.
The persistent negative FCF trajectory confirms that the company is in a high-intensity capital consumption phase. This trend appears likely to continue until clinical milestones are achieved, suggesting that the current cash position is insufficient to support long-term development without further dilutive financing.
According to recent SEC filings, working capital changes have been highly erratic, swinging from a $10.2 million outflow in 2023Q4 to a $5.0 million inflow in 2025Q2, which suggests that the company's cash management is heavily influenced by timing differences in vendor payments.
These sharp fluctuations in working capital suggest that management may be aggressively managing payables to preserve cash in the short term. Such tactics may provide temporary relief but do not address the fundamental lack of operational cash generation inherent in the current business model.
Analysis of the cash flow statement reveals that stock-based compensation, which reached $159.1K in 2025Q2, is being used to preserve cash, yet this non-cash expense fails to mitigate the underlying liquidity pressure caused by the company's substantial and recurring operating cash outflows.
The reliance on stock-based compensation as a non-cash expense suggests an attempt to conserve limited liquid assets, though this does not resolve the core issue of operational funding. Analysts should monitor whether this reliance on equity-based incentives will lead to significant future dilution for existing shareholders.
Quick answers to the most common questions about buying ESLA stock.
Estrella Immunopharma, Inc. (ESLA) generated $-1.8M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Estrella Immunopharma, Inc. (ESLA) reported negative free cash flow of $1.8M in 2025, indicating capital requirements exceeded cash from operations.
Estrella Immunopharma, Inc. (ESLA) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, Estrella Immunopharma, Inc. (ESLA) spent $0.0M on share repurchases. This shows the company's commitment to returning capital to its equity investors.